Cingulate Inc. (CINGW) Stock Price, Financials & Summary

Price chart

Sep 10Sep 18Sep 28Oct 2Oct 12Oct 15Oct 29Nov 4

Key dataNov 4, 2026

Open$0.00

From 52W high−96.96%

Volume0.00

Market cap$19009.22

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.00

From 52W high

−96.96%

Volume

0.00

Market cap

$19009.22

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.9x

P/E (TTM)

—

RSI (14)

44.3

MomentumView details →

1D Return

+0.00%

YTD Return

−93.60%

SummaryUpdated Jun 1, 2026

Cingulate Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Kansas City, Kansas. The company went public in December 2021 and focuses on developing innovative treatments for neurological and psychiatric disorders. Cingulate is currently advancing multiple drug candidates through clinical trials, with its primary focus on attention-deficit/hyperactivity disorder (ADHD) treatments and anxiety disorders.

Ask drillr about Cingulate Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−122.71%

ROA (TTM)

−87.09%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+13.02%

FCF YoY

−20.13%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+59.51%

EBITDA YoY

−37.89%

MomentumView details →

1D Return

+0.00%

YTD Return

−93.60%

1Y Return

−88.89%

RSI (14)

44.3

vs 50D SMA

−55.10%

vs 200D SMA

−90.07%

Capital & dividendView details →

Debt/Equity

0.27x

Current Ratio

3.50x

Quick Ratio

3.50x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.45

EPS Surprise

28.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.43

Avg Surprise (4Q)

27714.46%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−28.80M

Op. CF (TTM)

−20.65M

Next earningsNov 18, 2026 →

Latest newsMore news →

Cingulate Inc. reported a compensation change for Executive Vice President and Chief Medical Officer Matthew N. Brams, with a base salary of $400,000 effective September 30, 2026.33d ago

Cingulate Inc. reported its financial results for the second quarter ended June 30, 2026.83d ago

Similar companies

Pasithea Therapeutics Corp.KTTAW Carisma Therapeutics, Inc.CARM Cardio Diagnostics Holdings, Inc.CDIOW Syros Pharmaceuticals, Inc.SYRS Surrozen, Inc.SRZNW SAB Biotherapeutics, Inc.SABSW Find similar companies →

Latest newsMore news →

Cingulate Inc. reported a compensation change for Executive Vice President and Chief Medical Officer Matthew N. Brams, with a base salary of $400,000 effective September 30, 2026.33d ago Cingulate Inc. reported its financial results for the second quarter ended June 30, 2026.83d ago